Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program

Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

(2015) J. Richmond et al.   CLINICAL CANCER RESEARCH

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma

(2015) Doris Phelps et al.   PEDIATRIC BLOOD & CANCER

Identifying the determinants of response to MDM2 inhibition

(2015) Anne Y. Saiki et al.   Oncotarget

SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression

(2014) S. Wang et al.   CANCER RESEARCH

MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance

(2014) Giuseppe Barone et al.   CURRENT DRUG TARGETS

378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies

(2014) V. de Weger et al.   EUROPEAN JOURNAL OF CANCER

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

(2014) Daqing Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

(2014) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis

(2013) Camelia Iancu-Rubin et al.   EXPERIMENTAL HEMATOLOGY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

(2012) Hernan Carol et al.   PEDIATRIC BLOOD & CANCER

Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

(2011) T. Van Maerken et al.   MOLECULAR CANCER THERAPEUTICS

Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma

(2010) K. I. Pishas et al.   CLINICAL CANCER RESEARCH

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

(2010) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis

(2009) T Van Maerken et al.   CELL DEATH AND DIFFERENTIATION